Overview

The reference point every growth hormone secretagogue is implicitly compared against. Including it makes the comparison honest: rhGH is what actually happens when you raise growth hormone substantially, side effects included — and US law bans distributing it for anti-aging.

FDA ApprovedFDA-approved for growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, short bowel syndrome and several other indications. Distribution for anti-aging use is specifically prohibited by US federal law.

At a glance

Regulatory status	FDA-approved for growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, short bowel syndrome and several other indications. Distribution for anti-aging use is specifically prohibited by US federal law.
Drug class	191-amino-acid recombinant human growth hormone — a protein, not a short peptide
Route	Subcutaneous, daily (or weekly for long-acting analogs)
Half-life	~3–4 hours subcutaneously
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong Multiple phase 3 randomized trials plus regulatory approval in a major market.
Studied in	Decades of randomized trials across pediatric and adult deficiency states; large post-marketing safety registries such as KIGS and NordiNet.

How it works

Directly replaces growth hormone, binding the GH receptor to drive hepatic IGF-1 production, lipolysis, and protein anabolism. Unlike secretagogues it bypasses the pituitary entirely, producing sustained supraphysiological levels and suppressing endogenous secretion.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

One of the best-characterised hormone therapies in medicine, including a landmark trial showing harm in critical illness.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Restores growth in deficient children Strong evidence

Unambiguous, dose-dependent improvement in growth velocity and final adult height — the indication it was developed for.
Body composition in adult deficiency Strong evidence

Reduces fat mass and increases lean mass in genuine adult GH deficiency, with improved quality-of-life scores.
Bone density improvement Moderate evidence

Increases bone mineral density over multi-year treatment in deficient adults.
Multiple rare disease indications Strong evidence

Turner syndrome, Prader-Willi syndrome, SHOX deficiency and others, each with dedicated trial evidence.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Distributing it for anti-aging is a federal crime in the US Serious

GH is unusual: federal law restricts distribution to approved indications specifically, and prosecutions of anti-aging clinics have followed. This is not a grey area.
Insulin resistance and diabetes Serious

GH is directly counter-regulatory to insulin. New-onset type 2 diabetes is a recognised consequence of sustained therapy.
Fluid retention, arthralgia and carpal tunnel Moderate evidence

Dose-related and common in adults, sometimes limiting treatment.
Intracranial hypertension Serious

Uncommon but serious; presents with headache and visual change and requires prompt assessment.
Slipped capital femoral epiphysis in children Serious

A recognised orthopedic complication requiring surveillance during pediatric treatment.
Malignancy caution Serious

Contraindicated in active malignancy. Long-term registry data are broadly reassuring in deficiency, but not in healthy adults taking it to feel younger.
Suppresses the endogenous axis Moderate evidence

Unlike secretagogues, exogenous GH shuts down natural pituitary secretion.
Counterfeit market Serious

Widely counterfeited; seized products have contained no active ingredient or unidentified substances.

Who should avoid it

Active malignancy
Acute critical illness — a trial in ICU patients found increased mortality
Proliferative diabetic retinopathy
Closed epiphyses when used for height
Anti-aging or performance use

If used under medical supervision, monitor

IGF-1 targeted to age-adjusted reference range
Fasting glucose and HbA1c
Thyroid function
Fundoscopy if headache or visual symptoms
Growth velocity and hip examination in children

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

Corticosteroids — mutually antagonistic; both doses may need adjustment
Insulin and oral hypoglycemics — requirements typically increase
Oral estrogen — reduces GH responsiveness, higher doses often needed
CYP450 substrates — GH can alter clearance

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Sermorelin Limited Approval Evidence 3/5

Sermorelin stimulates your pituitary to release its own GH and preserves feedback control. Somatropin replaces GH directly, suppresses endogenous secretion, and carries the full acromegaly-like side effect profile.

Compare side by side

CJC-1295 Research Use Only Evidence 2/5

Marketing often implies these are equivalent. CJC-1295 has phase 1 data only; somatropin has decades of trials and a specific federal law governing its distribution.

Compare side by side

Regulatory & legal status

Prescription drug. US federal law (21 U.S.C. § 333(e)) prohibits distribution for any use other than approved indications, making anti-aging distribution a criminal offence.

Infographic

Somatropin (recombinant hGH) — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

growth hormoneproteinapprovedanti-aging illegalreference standard

Related peptides in Growth Hormone Axis

Terms used on this page

Growth Hormone Secretagogue (GHS): A growth hormone secretagogue is any compound that stimulates endogenous GH release, a class spanning GHRH analogues and ghrelin-mimetic agents acting at the GHS receptor.
Growth Hormone (GH): Growth hormone is a 191-amino-acid pituitary protein secreted in pulses that acts directly on tissues and indirectly through hepatic IGF-1, and is approved for a defined list of indications.
Adverse Drug Reaction (ADR): An adverse drug reaction is a noxious, unintended response to a medicine given at normal doses, and unlike an adverse event the term carries a causal judgement inside it.
Secretagogue: A secretagogue is a compound that causes a cell or gland to release a substance it already produces, acting upstream of the hormone rather than supplying the hormone itself.
Growth Hormone Receptor (GHR): The growth hormone receptor is a preformed cytokine-receptor dimer that a single GH molecule activates by binding two subunits at separate sites, signalling through JAK2 and STAT5b to induce IGF-1.
Insulin-Like Growth Factor 1 (IGF-1): IGF-1 is a 70-amino-acid, proinsulin-like peptide produced mainly by the liver under growth hormone control, and it mediates most of the anabolic effects attributed to growth hormone.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.